Nicolas Gendron on Sustainability in Anticoagulation and DOACs
Nicolas Gendron, Research Fellow, Hematologist at Boston Children’s Hospital, shared on LinkedIn:
”Anticoagulation and sustainability. What is the carbon impact of DOACs?
Our study, published in Haematologica Journal, compares for the first time the carbon footprint of the three DOACs used in France (dabigatran, apixaban, rivaroxaban) using two life cycle analysis databases, Ecovamed and MCF.
The main findings:
- DOACs do not have the same carbon footprint, despite similar efficacy and safety.
- Dabigatran has a much higher carbon impact than anti-Xa drugs (apixaban and rivaroxaban), with a footprint that is 3 to 36 times higher depending on the indications and databases.
- Most of dabigatran’s impact comes from its active ingredient, which is very energy-intensive to produce.
- Conversely, for apixaban and rivaroxaban, nearly 70% of the carbon impact is linked to corporate activities (RandD, distribution, administration, etc.).
- Lower doses, used for prolonged treatments, significantly reduce emissions.
DOACs are among the most widely prescribed drugs in the world.
At a time when the healthcare system needs to reduce its environmental footprint, these results show that, given equivalent efficacy and safety, the choice of treatment can have a major environmental impact.
Our study advocates for integrating environmental criteria into treatment decisions whenever possible, without ever compromising the quality of care.
Proud of this collective work.
Well done Laurence Chery, Zahra Hassani, Lise Durand, Dorothee Boisseau, Victorien Monguillon, David Grimaldi, Sebastien Taillemite, and Benjamin de Sainte Marie.
Thank you to Ecovamed for providing access to their high-quality data.
Thank you to SESAME.
Let’s continue to move towards cutting-edge, low-carbon medicine.”
Read the full article here.
Article: Carbon footprint of direct oral anticoagulants in atrial fibrillation and venous thromboembolism
Authors: Laurence Chery, Zahra Hassani, Lise Durand, Dorothee Boisseau, Victorien Monguillon, David Grimaldi, Sebastien Taillemite, Benjamin de Sainte Marie, Nicolas Gendron
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 30, 2026, 11:38Aaron Rodriguez Calienes on Intracranial Stenting: Rescue vs First-Line Outcomes
-
Jan 30, 2026, 11:25Ahmed Nasreldein on Sex Disparities in Thrombolysis Delay Among Egyptian Stroke Patients
-
Jan 30, 2026, 11:17Yanki Yarman: My PhD Project Has Been Published in Blood!
-
Jan 30, 2026, 11:08Alexandros Apostolou on Complications Associated with IDU and Thrombophilia
-
Jan 30, 2026, 10:57Peisong Ma on GRK5 Polymorphism Affecting Platelets
-
Jan 30, 2026, 10:47Ashok Yadav Explains Fetal Thrombotic Vasculopathy: FTV
-
Jan 30, 2026, 10:34Saif ur Rahman Compares K2 and K3 EDTA: Key Differences Explained
-
Jan 30, 2026, 10:22Manpreet Gill on Heparin Resistance: When 14 Years of Experience Finally Gets a Plot Twist
-
Jan 30, 2026, 10:14Mohamed Elsaid on The Role of Hyperlipidemia in Thrombogenesis